India's drug regulator CDSCO has found 53 drugs to be of non-standard quality in its latest test, which includes popular medicines like paracetamol, Vitamin D supplements, and antibiotics. These drugs are manufactured by various companies, including state-owned Hindustan Antibiotics. Some of these medicines were also linked to the deaths of 12 children in J&K in 2020, prompting tighter quality inspection measures in Gambia. In response to these findings, the CDSCO has revoked the power of state and UT authorities to grant no-objection-certificates for export purposes, and companies who received approvals in the past will have to report them to the central drug regulators. Stay updated with Fortune India on social media for more updates.